Annegret Bitzer - Concepedia

Author

Annegret Bitzer

University of Konstanz

Also Known As

Annegret Bitzer

Publications

552

Citations

H-Index

Concepts

All Affiliations

University of Konstanz Valneva (Austria)Biotechnology Institute Thurgau Vienna Biocenter

About

Annegret Bitzer is an author at University of Konstanz specializing in medicine, immunology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	246
2	Immunology	4	4	218
3	Cell Biology	2	2	83
4	Clinical Immunology	1	1	124
5	Global Health	1	1	28

Annegret Bitzer

Publications

538

Citations

H-Index

Page 1

	Year	Citations
Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial Martina Schneider, Marivic Narciso-Abraham, Sandra Hadl, The Lancet	2023	192
The immunoproteasome: a novel drug target for autoimmune diseases. Michael Basler, Sarah Mundt, Annegret Bitzer, PubMed Clinical ImmunologyNovel Drug TargetImmunodeficienciesImmunologyImmune Regulation	2015	124
Effectiveness of CHIKV vaccine VLA1553 demonstrated by passive transfer of human sera Pierre Roques, Andrea Fritzer, Nathalie Dereuddre‐Bosquet, JCI Insight	2022	68
Stable Antigen Is Most Effective for Eliciting CD8<sup>+</sup>T-Cell Responses after DNA Vaccination and Infection with Recombinant Vaccinia Virus<i>In Vivo</i> Christopher Schliehe, Annegret Bitzer, Maries van den Broek, Journal of Virology Viral ImmunityImmunologyAntigen ProcessingCd4 T Cell ResponsesImmunotherapy	2012	46
Immunoproteasome subunit deficiency has no influence on the canonical pathway of NF-κB activation Annegret Bitzer, Michael Basler, Daniel Krappmann, Molecular Immunology InflammationCytokineMolecular ImmunologyDisease MechanismImmune Cell Development	2017	37
A randomized, double-blinded Phase 3 study to demonstrate lot-to-lot consistency and to confirm immunogenicity and safety of the live-attenuated chikungunya virus vaccine candidate VLA1553 in healthy adults Robert P. McMahon, Ulrike Fuchs, Martina Schneider, Journal of Travel Medicine	2023	32
Safety and immunogenicity of a live-attenuated chikungunya virus vaccine in endemic areas of Brazil: interim results of a double-blind, randomised, placebo-controlled phase 3 trial in adolescents Vera Buerger, Sandra Hadl, Martina Schneider, The Lancet Infectious Diseases VaccinationVaccine SafetyVaccine DevelopmentPlacebo-controlled Phase 3Global Health	2024	28
Chaperone BAG6 is dispensable for MHC class I antigen processing and presentation Annegret Bitzer, Michael Basler, Marcus Groettrup Molecular Immunology HistocompatibilityChaperone Bag6Mhc ClassImmunologyAntigen Processing	2015	11

Page 1